Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study
- 1 June 2012
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (6) , 2059-2067
Abstract
Cytotoxic treatment may accelerate depletion of the primordial follicle pool, leading to impaired fertility and premature menopause. Assessment of ovarian damage in prepubertal girls is not currently possible, but Anti-Müllerian Hormone (AMH) is a useful marker of ovarian reserve in adults. The objective of the study was to prospectively evaluate AMH measurement in children as a marker of ovarian toxicity during cancer treatment. This was a prospective, longitudinal study at a University Hospital. Twenty-two females (17 prepubertal), median age 4.4 yr (range 0.3-15 yr), were recruited before treatment for cancer. AMH, inhibin B, and FSH at diagnosis, after each chemotherapy course and during follow-up, were measured. Risk of gonadotoxicity was classified as low/medium (n = 13) or high (n = 9) based on chemotherapy agent, cumulative dose, and radiotherapy involving the ovaries. Pretreatment AMH was detectable across the age range studied. AMH decreased progressively during chemotherapy (P < 0.0001) in both prepubertal and pubertal girls, becoming undetectable in 50% of patients, with recovery in the low/medium risk groups after completion of treatment. In the high-risk group, AMH became undetectable in all patients and showed no recovery. Inhibin B was undetectable in most patients before treatment and, with FSH, showed no clear relationship to treatment. AMH is detectable in girls of all ages and falls rapidly during cancer treatment in both prepubertal and pubertal girls. Both the fall during treatment and recovery thereafter varied with risk of gonadotoxicity. AMH is therefore a clinically useful marker of damage to the ovarian reserve in girls receiving treatment for cancer.Keywords
This publication has 36 references indexed in Scilit:
- A Validated Model of Serum Anti-Müllerian Hormone from Conception to MenopausePLOS ONE, 2011
- Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patientsFertility and Sterility, 2011
- Serum Levels of Anti-Müllerian Hormone as a Marker of Ovarian Function in 926 Healthy Females from Birth to Adulthood and in 172 Turner Syndrome PatientsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Fertility of Female Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2009
- Ovarian Failure and Reproductive Outcomes After Childhood Cancer Treatment: Results From the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2009
- Premature Menopause in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor StudyJNCI: Journal of the National Cancer Institute, 2006
- Predicting age of ovarian failure after radiation to a field that includes the ovariesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitmentMolecular Human Reproduction, 2004
- Serum anti-Mullerian hormone levels: a novel measure of ovarian reserveHuman Reproduction, 2002
- Late Mortality Experience in Five-Year Survivors of Childhood and Adolescent Cancer: The Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2001